BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27322214)

  • 1. Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.
    Grosicki S; Barchnicka A
    Expert Rev Hematol; 2016 Jul; 9(7):621-8. PubMed ID: 27322214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elotuzumab for the treatment of multiple myeloma.
    Moreau P; Touzeau C
    Future Oncol; 2014 May; 10(6):949-56. PubMed ID: 24941981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elotuzumab as a novel anti-myeloma immunotherapy.
    Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
    Friend R; Bhutani M; Voorhees PM; Usmani SZ
    Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Laubach J; Richardson P
    Expert Opin Biol Ther; 2013 Dec; 13(12):1731-40. PubMed ID: 24151843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
    Comeau JM; Kelly K; Jean GW
    Am J Health Syst Pharm; 2018 Jan; 75(2):55-66. PubMed ID: 29317395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of SLAMF7 in multiple myeloma: impact on therapy.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Clin Immunol; 2017 Jan; 13(1):67-75. PubMed ID: 27376202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elotuzumab: First Global Approval.
    Markham A
    Drugs; 2016 Mar; 76(3):397-403. PubMed ID: 26809244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elotuzumab for the treatment of multiple myeloma.
    Wang Y; Sanchez L; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jul; 9(1):55. PubMed ID: 27417553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
    Grosicki S; Bednarczyk M; Barchnicka A; Grosicka O
    Future Oncol; 2021 May; 17(13):1581-1591. PubMed ID: 33478270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
    Offidani M; Corvatta L
    Future Oncol; 2018 Feb; 14(4):319-329. PubMed ID: 29091475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.
    Lonial S
    Cancer J; 2016; 22(1):3-6. PubMed ID: 26841009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
    Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
    Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elotuzumab May Slow Multiple Myeloma.
    Cancer Discov; 2015 Jul; 5(7):OF10. PubMed ID: 25998398
    [No Abstract]   [Full Text] [Related]  

  • 20. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
    Veillette A; Guo H
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):168-77. PubMed ID: 23731618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.